Alex Goldberg

MannKind Corp. (NASDAQ:MNKD) and Mylan, Inc. (NASDAQ:MYL) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 01/15/2014 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding MannKind Corp. (NASDAQ:MNKD) and Mylan, Inc. (NASDAQ:MYL).

MannKind Corp. (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States is currently down (-0.17%) on 6,183,166 shares traded. MannKind Corp. (NASDAQ:MNKD) is currently down (-33.33%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about MannKind Corp. (NASDAQ:MNKD)

Mylan, Inc. (NASDAQ:MYL) a company that engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients worldwide is currently down (-1.51%) on 2,200,269 shares traded. Mylan, Inc. (NASDAQ:MYL) is currently down (-2.05%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Mylan, Inc. (NASDAQ:MYL)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com